v3.25.4
Collaboration Agreements (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2023
May 31, 2022
May 31, 2018
Mar. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2019
Jun. 26, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from collection of notes receivable $ 12,000,000.0                
Discount rate 3.75%                
Gain (loss) on extinguishment of debt         $ 0 $ 0 $ (313,000)    
Contract liabilities, net of current portion         18,669,000 18,669,000      
Revenue         0 1,017,000 $ 0    
G42 Investments                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Shares sold (in shares)   259,657              
Sale of stock, consideration received on transaction, gross   $ 25,000,000.0              
Aggregate gross purchase price   12,500,000              
Accounts and financing receivable, after allowance for credit loss   12,500,000              
Proceeds from collection of notes receivable $ 12,000,000.0                
Discount rate 3.75%                
Gain (loss) on extinguishment of debt $ (300,000)                
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Sale of stock, consideration received on transaction, gross   25,000,000.0              
Accounts and financing receivable, after allowance for credit loss   12,500,000              
Gain (loss) on extinguishment of debt $ (300,000)                
Contingent consideration transferred, aggregate share value   30,000,000.0              
Contingent consideration transferred, cash   $ 30,000,000.0              
Contract liabilities, net of current portion         18,700,000 18,700,000      
Note receivable, discount paid         600,000        
Revenue from collaborative arrangement         0        
Revenue         0 $ 0      
Receivables, fair value disclosure         $ 11,900,000        
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, royalties receivable, period   10 years              
Collaborative Arrangements | Newsoara Biopharma Co., Ltd.                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue recognized       $ 1,000,000.0          
Collaborative Arrangements | Newsoara Biopharma Co., Ltd.                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License fee received     $ 2,000,000.0            
Potential development and regulatory milestone payments                 $ 76,500,000
Collaboration revenue recognized               $ 1,000,000.0